DexCom (DXCM) Stock Analysis & AI Equity Report
DexCom (DXCM) overview
DexCom (DXCM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4,662m and operating profit of USD 912m; the year-end share price was 66.37 USD and market capitalisation was USD 25,539m. DexCom is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get DexCom's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About DexCom
Dexcom designs, develops and commercializes continuous glucose monitoring systems for diabetes and metabolic health management. Its products include the G7 and G7 15 Day systems and Stelo, an over-the-counter biosensor for adults with prediabetes or type 2 diabetes who do not use insulin. Users include patients, caregivers and clinicians, with compatible display devices and reporting software supporting glucose monitoring and care coordination.
Generate the DexCom report
DexCom is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for DexCom and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on DexCom
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.